Adagene (ADAG)
(Delayed Data from NSDQ)
$2.55 USD
-0.02 (-0.78%)
Updated May 17, 2024 03:58 PM ET
After-Market: $2.54 -0.01 (-0.39%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ADAG 2.55 -0.02(-0.78%)
Will ADAG be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ADAG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADAG
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
Are Medical Stocks Lagging Medpace (MEDP) This Year?
ADAG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Other News for ADAG
Analysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Adagene (ADAG) and Aquestive Therapeutics (AQST)
12 Health Care Stocks Moving In Monday's Intraday Session
Adagene ADR Non-GAAP EPS of -$0.21, revenue of $18.11M
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
Adagene’s Breakthroughs Promise Future Growth